Brain cancer combo shows promise in early study
NCT ID NCT06115824
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 28 times
Summary
This study looked at 136 people with newly diagnosed primary central nervous system lymphoma, a rare brain cancer. Researchers compared standard chemotherapy alone to chemotherapy plus a targeted drug called orelabrutinib. The goal was to see if the combination improved tumor shrinkage and delayed cancer progression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of Hematology, Huashan Hospital, Fudan University
Shanghai, China
Conditions
Explore the condition pages connected to this study.